Oncology field still wide open - Roche failureLooks like Roche's anti-TIGIT (Immunotherapy) combo trial for non small cell lung failed. They comboed their anti-TIGIT with a PD-1 and it missed the mark. It is an immunotherapy approach, so not a comp for THTX. There are a few other anti-TIGIT's constructed a bit differently that are trying to do the same, so the category (which was all the rage at last years conferences) is not yet done for, but certainly dented in NSCL cancers.